Chugai Pharma USA

Chugai Pharma USA products

A

• Alecensa® — alectinib
  Indication: ALK-positive, advanced or recurrent non–small cell lung cancer; also used as adjuvant therapy

• Actemra® — tocilizumab
  Indications: rheumatoid arthritis, adult Still’s disease, Castleman’s disease, and COVID-19 pneumonia requiring oxygen support

E

• Enspryng® — satralizumab
  Indication: neuromyelitis optica spectrum disorder (NMOSD)

• Evrysdi® — risdiplam
  Indication: treatment of spinal muscular atrophy

H

• Hemlibra® — emicizumab
  Indication: prophylaxis for hemophilia A with or without factor VIII inhibitors

O

• **Ongoing Oncology Biosimilars**
  (e.g., Avastin® /bevacizumab, Herceptin® /trastuzumab, Kadcyla® /trastuzumab emtansine, Perjeta® /pertuzumab, Tecentriq® /atezolizumab, Lunsumio® /mosunetuzumab, Polivy® /polatuzumab vedotin, Phesgo® (combo) )
  Indications: various cancer types, including breast, colorectal, lung cancer, and lymphoma

T

• Tamiflu® — oseltamivir
  Indication: treatment of influenza